Pavmed Inc PAVM

$2.87 +0.17 (6.30%)

Valuation

Market cap: 21,589,000
Revenue TTM: $70,000
Net income TTM: $400,000
PE ratio: 0.00
Forward PE: —
Profit margin: 571.43%
Debt to equity: 0.78

Trading

Volume: 28,500
Avg volume: 34,588
Day's range: $2.65 – $2.99
Shares out: 7,996,000
Stochastic %K: 15%
Beta: 0.70
Analysts: Sell
Price target: $36.50

Price

Company profile

PAVmed Inc. engages in acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck device. Its product pipeline also comprises EsoCure Esophageal Ablation Device for treating dysplastic BE; PortIO, an implantable intraosseous vascular access device; and Veris cancer care platform. The company was formerly known as PAXmed Inc. and changed its name to PAVmed Inc. in April 2015. PAVmed Inc. was incorporated in 2014 and is headquartered in New York, New York.

Industry: Medical Devices
Sector: Healthcare
Phone: 917 813 1828
Website: https://www.pavmed.com
Address: 360 Madison Avenue, 25th Floor, New York, United States

Latest news

No headlines yet.

Stocktwits

chuckjackson Oct 3, 6:49 PM

$LUCD $PAVM I believe pavm has pretty much tapped out the latest atm unless the stock price goes up significantly. Public float is about 4.1M. Public float market cap is about $11.767. Because of the baby shelf rule, they can only run the atm for a third of the public float market cap over a 1 year rolling period. So they can extract only $3.92M. During 4/1/26 to 6/30/26, they raised $1.2-1.4M. During 7/1/26 to 8/13/26 they raised $2.8M. So even though they initiated a new $9.4M atm, they are unable to sell an additional shares until 4/1/27 to 6/30/27 or is the stock price goes up because of the crash in the stock price. In terms of liquidity, the cash balance at the end of June 2026 was $3.8M + $2.8M from the atm in Jul-Aug along with monthly cash burn of $900K means they are out of cash by Feb 2027. I don't think they can sell too many of theit lucd shares because of minimum shareholder equity requirements (I will need to do the calculation).

1 replies

dmc4321 Oct 2, 9:33 AM

$LUCD & $PAVM I have said MULTIPLE TIMES for over a year that LUCD would trade at 50 cents or lower in 2026. Just so you know I feel that the current situation is worse than my worst case thinking when i made that prediction in 2025. "Buy the dip" or "catch a falling knife". I know which one it probably is. Remember that we haven't even entered the tax loss selling season. The analysts are positioning themselves to be book runners on the next financing so there words are tainted and should not be relied upon. It's your hard earned money so don't squander it please.

0 replies

chuckjackson Oct 1, 11:07 PM

$PAVM $LUCD to be honest, i thought the stocks would be weak for the next 3 months but the large drops today shook me. I thought I would have the chance to do some tax loss selling at a reasonable price but that is now out the window. Whoever sold today sold at a loss (unless there were warrant or convertible holders who got in at a good deal). One thing I'm wondering is whether the company hammered away at the atm given that they can't get the draft until next year at the earliest

1 replies

Investbythenumbers Oct 1, 7:33 PM

$PAVM Bullish!

0 replies

Heywood_Jablomi Oct 1, 4:20 PM

$PAVM in

0 replies

TopCharts Oct 1, 4:04 PM

$PAVM brutal

0 replies

chuckjackson Oct 1, 3:26 PM

$PAVM $LUCD I thought about tax loss selling but the losses at these prices would be difficult to swallow

1 replies

chuckjackson Sep 30, 9:07 PM

$PAVM $LUCD so here's the deal. Tonight may be the last chance for a draft for 2026. For drafts released tonight, the 45day review period will end on Nov 15. The following week will start the holidays with Thanksgiving week. My assumption is after this week, the next chance for a draft will be next year to avoid overlap with the holidays. The bad news is that it means 3 months of cash burn. Here are the consequences. 1) lucd has been trading under $1.X for 25 days. They will most likely go out of compliance in a few days without a draft tonight. 2) They are running low on cash and will feel pressured to raise funds. They will find it hard to raise funds on favorable terms if they are out of compliance and will be forced to do a reverse split soon. 3) the 3 month delay is even more problematic for pavm as they are low in cash and have no means of generating revenue and will drive the stock further into the ground with the atm.

4 replies